
Clinician's Roundtable
Evaluating the Safety of Ixekizumab in Psoriasis and Arthritis Patients
Mar 18, 2025
00:00
Guest: Atul A. Deodhar, MD, MRCP
Based on data from 25 studies, ixekizumab has a lower risk of common adverse events like depression, cardiovascular events, cancer, and uveitis that are often seen with other treatments for psoriasis, psoriatic arthritis, and axial spondyloarthritis. Here to share the safety findings on ixekizumab is Dr. Atul Deodhar, Professor of Medicine and the Medical Director of Rheumatology Clinics at Oregon Health & Science University
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.